FlowCardia, Inc. Launches Peripheral CROSSER(R) Catheter Portfolio in the US

SUNNYVALE, Calif., Dec. 11 /PRNewswire/ -- FlowCardia, Inc., a medical device company developing a portfolio of endovascular devices for the treatment of coronary and peripheral chronic total occlusions (CTOs), announced FDA 510(k) clearance and immediate U.S. launch of the CROSSER 14P, CROSSER 14S and CROSSER 18 CTO Recanalization Catheters.
The three peripheral CROSSER Catheters are endovascular tools used by interventional radiologists, vascular surgeons and interventional cardiologists to cross CTOs to help restore blood flow to the lower legs. The CROSSER is a rapid exchange catheter delivered over standard .014" and .018" guidewires that utilizes high frequency vibration to cross CTOs allowing for subsequent debulking, balloon angioplasty and stent placement. The peripheral CROSSER Catheters were studied in the FlowCardia PATRIOT Trial.

read the full article >> http://www.earthtimes.org/articles/show/news_press_release,240199.shtml